Haraguchi Yoshiaki, Shimizu Hideo, Takahashi Makoto, Nakano Makoto, Okusawa Atsushi, Suzuki Masaaki
Dept. of Surgery, Matsumura General Hospital.
Gan To Kagaku Ryoho. 2004 Mar;31(3):419-22.
We performed combined chemotherapy of low-dose CPT-11 and 5'-DFUR as second-line chemotherapy in 2 cases of non-resectable metastatic or recurrent rectal cancer. The first patient was a 61-year-old male who had rectal cancer with liver and lung metastases. The second patient was a 76-year-old male who had initial recurrent rectal cancer with multiple liver metastases. Both patients were given first-line chemotherapy of 5-FU + l-LV. CPT-11 was administered at 60 mg/body on day 1, 8 and 15 of a 4-week course by intravenous infusion as outpatient treatment. Furthermore, 5'-DFUR was administered orally at 800 mg/body every day. Consequently, we obtained a decrease in the tumor markers and a reduction of liver metastases in 2 patients after 3 months, Adverse reactions such as myelosuppression and diarrhea were not observed. This treatment could be continued in safety with good QOL on an outpatient basis. These cases suggest that this combined chemotherapy of low-dose CPT-11 and 5'-DFUR may be an effective treatment for non-resectable colorectal cancer in the future.
我们对2例不可切除的转移性或复发性直肠癌患者进行了低剂量伊立替康（CPT-11）和去氧氟尿苷（5'-DFUR）的联合化疗作为二线化疗。首例患者为一名61岁男性，患有伴有肝和肺转移的直肠癌。第二例患者为一名76岁男性，患有初发复发性直肠癌伴多发肝转移。两名患者均接受了氟尿嘧啶（5-FU）+亚叶酸钙（l-LV）的一线化疗。伊立替康在4周疗程的第1、8和15天以60mg/体静脉输注的方式作为门诊治疗给药。此外，去氧氟尿苷每天口服800mg/体。结果，3个月后2例患者的肿瘤标志物均下降，肝转移灶缩小，未观察到骨髓抑制和腹泻等不良反应。这种治疗可以在门诊安全地持续进行，患者生活质量良好。这些病例表明，低剂量伊立替康和去氧氟尿苷的这种联合化疗未来可能是不可切除结直肠癌的一种有效治疗方法。
